-
公开(公告)号:US20240344102A1
公开(公告)日:2024-10-17
申请号:US18431564
申请日:2024-02-02
申请人: Merus N.V.
IPC分类号: C12P21/00 , A61K39/395 , A61K39/40 , C07K16/12 , C07K16/18 , C07K16/26 , C07K16/28 , C07K16/36 , C07K16/46 , A61K39/00
CPC分类号: C12P21/005 , A61K39/395 , A61K39/3955 , A61K39/40 , C07K16/12 , C07K16/1278 , C07K16/1282 , C07K16/18 , C07K16/26 , C07K16/28 , C07K16/2809 , C07K16/283 , C07K16/2866 , C07K16/2896 , C07K16/36 , C07K16/468 , A61K2039/507 , C07K2317/14 , C07K2317/31 , C07K2317/526 , C07K2317/56 , C07K2317/94
摘要: The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided.
-
公开(公告)号:US12084519B2
公开(公告)日:2024-09-10
申请号:US17371762
申请日:2021-07-09
发明人: Charles B. Shoemaker , Hanping Feng
CPC分类号: C07K16/468 , A61K38/16 , A61K39/39591 , C07K16/1282 , C07K16/40 , C07K16/44 , A61K2039/505 , A61K2039/507 , C07K2317/31 , C07K2317/569 , C07K2317/62 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C07K2319/40
摘要: Methods, compositions and kits are provided for treating a subject exposed to or at risk for exposure to a disease agent using a pharmaceutical composition including at least one recombinant heteromultimeric neutralizing binding protein including two or multiple binding regions, such that the binding regions are not identical, and each binding region specifically binds a non-overlapping portion of the disease agent, thereby treating the subject for exposure to the disease agent. In a related embodiment, the heteromultimeric neutralizing binding protein includes two or multiple binding regions that neutralize a plurality of disease agents. In certain embodiments, the disease agent includes a bacterium, a bacterial protein, a virus, a viral protein, a cancer cell, and a protein or molecule produced therefrom. In certain embodiments, the disease agent is a plurality of different disease agents.
-
公开(公告)号:US11993643B2
公开(公告)日:2024-05-28
申请号:US17372966
申请日:2021-07-12
发明人: Jamshid Tanha
CPC分类号: C07K16/005 , C07K16/1271 , C07K16/1282 , C12N15/1037 , G01N33/6845 , C07K2317/21 , C07K2317/56 , C07K2317/92 , C07K2317/94
摘要: Polypeptides with biophysical properties such as solubility, stability, high expression, monomericity, binding specificity or non-aggregation, including monomeric human heavy and light chain variable domains (VHs and VLs), are identified using a high throughput method for screening polypeptides, comprising the steps of obtaining a phage display library, allowing infection of a bacterial lawn by the library phage, and identifying phage which form larger than average plaques on the bacterial lawn. Sequences of monomeric human VHs and VLs are identified, which may be useful for immunotherapy or as diagnostic agents. Multimer complexes of human VHs and VLs are also identified. The VHs and VLs identified may be used to create further libraries for identifying additional polypeptides. Further, the VHs and VLs may be subjected to DNA shuffling to select for improved biophysical properties.
-
公开(公告)号:US20240150446A1
公开(公告)日:2024-05-09
申请号:US18505543
申请日:2023-11-09
申请人: Daro Zist Azma Oxin
发明人: Zohre BAZAZ , Masoume BAZAZ
IPC分类号: C07K16/12 , C12N5/0781
CPC分类号: C07K16/1282 , C12N5/0635 , C07K2317/14 , C07K2317/21 , C07K2317/622 , C12N2500/25 , C12N2500/30 , C12N2501/999 , C12N2502/1358
摘要: A method for producing an antibody fragment from one or more single plasma cells. The method comprises obtaining a plurality of plasma cells, preparing a plurality of modified cell culture substrates, seeding each respective plasma cell of the plurality of plasma cells on the each respective modified cell culture substrate of the plurality of modified cell culture substrates, forming a plurality of cultured single plasma cells by culturing the seeded each respective plasma cell in a culture medium for a time duration of at least 10 days, and detecting the one or more single plasma cells that secrete the antibody fragment from among the plurality of cultured single plasma cells. The culture medium comprises a conditioned medium harvested from a culture of h-BMSCs, Insulin, Transferrin, Selenium, and Pyruvate.
-
公开(公告)号:US11926859B2
公开(公告)日:2024-03-12
申请号:US18318507
申请日:2023-05-16
申请人: Merus N.V.
IPC分类号: C12N15/00 , A61K39/395 , A61K39/40 , C07K16/12 , C07K16/18 , C07K16/26 , C07K16/28 , C07K16/36 , C07K16/46 , C12P21/00 , A61K39/00
CPC分类号: C12P21/005 , A61K39/395 , A61K39/3955 , A61K39/40 , C07K16/12 , C07K16/1278 , C07K16/1282 , C07K16/18 , C07K16/26 , C07K16/28 , C07K16/2809 , C07K16/283 , C07K16/2866 , C07K16/2896 , C07K16/36 , C07K16/468 , A61K2039/507 , C07K2317/14 , C07K2317/31 , C07K2317/526 , C07K2317/56 , C07K2317/94
摘要: The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided.
-
公开(公告)号:US20240043503A1
公开(公告)日:2024-02-08
申请号:US18378021
申请日:2023-10-09
IPC分类号: C07K16/06 , A61K39/395 , A61K39/42 , C07K16/08 , C07K16/10 , A61K39/155 , A61K45/06 , G01N33/68 , C07K16/12
CPC分类号: C07K16/06 , A61K39/39516 , A61K39/42 , C07K16/08 , C07K16/1027 , A61K39/155 , A61K45/06 , C07K16/10 , G01N33/6854 , C07K16/1009 , C07K16/1203 , C07K16/1232 , C07K16/1242 , C07K16/1271 , C07K16/1275 , C07K16/1282 , C07K16/1285 , C07K16/1289 , A61K2039/507
摘要: The present invention relates to compositions and methods for the treatment of immunodeficiency (e.g., primary immunodeficiency disease). In particular, the invention provides human plasma immunoglobulin compositions containing select antibody titers specific for a plurality of respiratory pathogens, methods of identifying human donors and donor samples for use in the compositions, methods of manufacturing the compositions, and methods of utilizing the compositions (e.g., for prophylactic administration and/or therapeutic treatment (e.g., passive immunization (e.g., immune-prophylaxis))).
-
公开(公告)号:US11785924B2
公开(公告)日:2023-10-17
申请号:US15863787
申请日:2018-01-05
申请人: Merus N.V.
发明人: Ton Logtenberg , Mark Throsby , Robert A. Kramer , Rui Daniel Pinto , Cornelis A. De Kruif , Erwin Houtzager
IPC分类号: A01K67/027 , C12N15/85 , C07K16/46 , C07K16/00 , C12N5/10 , C07K16/10 , C07K16/22 , C07K16/28 , C07K14/47 , C07K16/32 , G01N33/569 , C07K16/24 , C12P21/00 , C07K16/12
CPC分类号: A01K67/0278 , A01K67/027 , A01K67/0275 , C07K16/00 , C07K16/462 , C12N5/10 , C12N15/8509 , A01K2207/15 , A01K2217/052 , A01K2217/075 , A01K2217/15 , A01K2217/206 , A01K2227/105 , A01K2267/01 , C07K14/47 , C07K16/005 , C07K16/10 , C07K16/1282 , C07K16/22 , C07K16/248 , C07K16/2863 , C07K16/32 , C07K2317/10 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/622 , C07K2317/64 , C07K2317/76 , C07K2317/94 , C07K2319/00 , C12P21/00 , G01N33/56966
摘要: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.
-
公开(公告)号:US20230323290A1
公开(公告)日:2023-10-12
申请号:US17884069
申请日:2022-08-09
申请人: Allergan, Inc.
CPC分类号: C12N5/0618 , C07K16/1282 , C12N5/0693 , G01N33/5014 , G01N33/5058 , G01N33/5091 , G01N33/567
摘要: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.
-
公开(公告)号:US20230293731A1
公开(公告)日:2023-09-21
申请号:US18147365
申请日:2022-12-28
申请人: CureVac SE
CPC分类号: A61K48/0066 , C07K16/10 , C07K16/1018 , C07K16/1027 , C07K16/1045 , C07K16/1282 , C07K16/2803 , C07K16/2809 , C07K16/2863 , C07K16/2887 , C07K16/32 , C12N15/85 , A61K2039/505
摘要: The present invention relates to a RNA encoding an antibody or a fragment or variant thereof and a composition, in particular a passive vaccine, comprising such an RNA. The present invention further relates to the use of such an RNA or of such a composition for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. also in gene therapy. The present invention also relates to a combination of at least two modified RNA's, in particular wherein one RNA encodes a heavy chain variable region of an antibody and another RNA encodes the corresponding light chain variable region of said antibody.
-
公开(公告)号:US11725046B2
公开(公告)日:2023-08-15
申请号:US16958213
申请日:2018-12-28
发明人: Huaxin Liao , Yueming Wang , Xiaohui Yuan , Weihong Zheng
IPC分类号: C07K16/12 , G01N33/569 , G01N33/577
CPC分类号: C07K16/1282 , G01N33/56911 , G01N33/577 , C07K2317/21 , C07K2317/76 , C07K2317/92 , G01N2333/33
摘要: The invention describes fully native human neutralizing monoclonal antibodies against tetanus toxin. The invention developed fully native human neutralizing monoclonal antibodies against tetanus toxin through a systematic high through-put platform that is specialized for identifying and developing human native antibody. The neutralizing monoclonal antibodies described in the invention can be used in the prevention, treatment and detection of Clostridium tetani infection. The fully human neutralizing monoclonal antibodies developed in the invention have a high affinity toward tetanus toxin, as well as possessing high neutralizing activities against the toxin, safe of use with high disease prevention effectiveness, free of exogenous virus contamination, and are widely applicable to various human groups with strong industrial applications.
-
-
-
-
-
-
-
-
-